Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

By Bao Philip   Ramanathan Ramesh   Krasinkas Alyssa   Bahary Nathan   Lembersky Barry   Bartlett David   Hughes Steven   Lee Kenneth   Moser A.   Zeh Herbert  

Annals of Surgical Oncology, Vol. 18, Iss. 4, 2011-04 ,pp. : 1122-1129

Springer Publishing Company

Access to resources Recommend Favorite

Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy

By Vogl Thomas   Schwarz Wolfram   Eichler Katrin   Hochmuth Kathrin   Hammerstingl Renate   Jacob Ursula   Scheller Albert   Zangos Stephan   Heller Matthias  

Journal of Cancer Research and Clinical Oncology, Vol. 132, Iss. 11, 2006-11 ,pp. : 745-755

Springer Publishing Company

Access to resources Recommend Favorite

Intraperitoneal chemotherapy for the treatment of ovarian cancer

By Dorff Tanya  

The Women's Oncology Review, Vol. 5, Iss. 4, 2005-12 ,pp. : 203-211

Informa Healthcare

Access to resources Recommend Favorite

Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy

By Morinaga Soichiro   Nakamura Yoshiyasu   Watanabe Takuo   Mikayama Hiroshi   Tamagawa Hiroshi   Yamamoto Naoto   Shiozawa Manabu   Akaike Makoto   Ohkawa Shinnichi   Kameda Yoichi   Miyagi Yohei  

Annals of Surgical Oncology, Vol. 19, Iss. 3, 2012-07 ,pp. : 558-564

Springer Publishing Company

Access to resources Recommend Favorite

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer

By Boeck Stefan   Heinemann Volker  

Future Oncology, Vol. 4, Iss. 1, 2008-02 ,pp. : 41-50

Future Medicine

Access to resources Recommend Favorite